Close

StreetInsider.com After-Hours Movers 11/06: (BKE) (NWSA) (PFE) Higher; (PLXS) (LPSN) (ALXA) Lower (more...)

November 6, 2012 6:10 PM EST
Plexus Corp. (Nasdaq: PLXS) 23% LOWER; today announced its disengagement as a supplier to Juniper Networks, Inc. (NYSE: JNPR). Plexus was informed of the disengagement on Monday, November 5, 2012. The timing of the transition of Juniper business from Plexus is not yet known, although it is currently expected to occur by the end of our current fiscal year.

LivePerson, Inc. (NASDAQ: LPSN) 14% LOWER; reported Q3 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $36.1 million versus the consensus estimate of $41.05 million. LivePerson, Inc. sees Q4 2012 EPS of $0.07-0.09, versus the consensus of $0.10. LivePerson, Inc. sees Q4 2012 revenue of $41.5-42.0 million, versus the consensus of $44.7 million. LivePerson, Inc. sees FY2012 EPS of $0.30-0.33, versus the consensus of $0.32. LivePerson, Inc. sees FY2012 revenue of $156.5-157.0 million, versus the consensus of $160.98 million

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) 8% LOWER; reported Q3 EPS of ($0.52), versus ($1.86) reported last year. Revenue for the quarter came in at $729 thousand, versus $1.86 million reported last year.

EZCORP, Inc. (NASDAQ: EZPW) 8% LOWER; reported Q4 EPS of $0.75, in-line with the analyst estimate of $0.75. Revenue for the quarter came in at $258.4 million versus the consensus estimate of $256.54 million. Ezcorp, Inc. sees FY2013 EPS of $2.55-2.80, versus the consensus of $3.22. Ezcorp, Inc. sees Q1 2013 EPS of $0.55-0.60, versus the consensus of $0.82

Buckle Inc. (NYSE: BKE) 5% HIGHER; Special dividend.

KAR Auction Services (NYSE: KAR) 4% LOWER; reported Q3 EPS of $0.23, $0.03 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $474.9 million versus the consensus estimate of $474.26 million. KAR Auction Services sees FY2012 EPS of $1.00-1.05, versus the consensus of $1.08.

News Corp (NASDAQ: NWSA) 3% HIGHER; reported Q1 EPS of $0.43, $0.05 better than the analyst estimate of $0.38. Revenue for the quarter came in at $8.41 billion versus the consensus estimate of $8.16 billion.

Pfizer (NYSE: PFE) 2% HIGHER; Receives FDA Approval for XELJANZ as RA Treatment


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Dividend, After-Hours Movers